Neurotransmitter Systems in Clinical Practice

A medication can improve one neural circuit and destabilize another. Clinical reasoning is therefore more reliable when it starts with the signal being altered, the exposure that altered it, and the neurological pattern that followed. Four systems recur in drug-treated neurological and psychiatric illness. Dopamine loss produces parkinsonian motor features, while dopamine-receptor blockade or abrupt withdrawal of dopaminergic therapy can produce a malignant syndrome. Excess serotonergic activity produces serotonin toxicity. GABA provides the brain’s main inhibitory brake; glutamate provides its main excitatory drive. Benzodiazepines strengthen GABA-A inhibition, whereas NMDA-receptor antagonists such as esketamine modify glutamatergic signalling. The practical question is not whether a patient has a single neurotransmitter deficiency. Ask instead: what changed, how quickly did it change, and does the examination fit the suspected drug effect? That sequence helps separate serotonin syndrome from neuroleptic malignant syndrome, prevents unsafe interruption of Parkinson therapy, and identifies when sedation or anticonvulsant treatment can become respiratory-depressant.